Ustekinumab in the treatment of palmoplantar pustulosis

Gerdes, Sascha; Franke, Jöerg; Domm, Silja; Mrowietz, Ulrich

doi:10.1111/j.1365-2133.2010.09897.x

Cited by 73 publications

(60 citation statements)

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Effective treatment of refractory TNF inhibitor-induced palmoplantar pustulosis with ustekinumab has recently been reported in 2 women with Crohn’s disease and rheumatoid arthritis, respectively [14]. A small case series of 4 patients with recalcitrant palmoplantar pustulosis treated with ustekinumab, with a satisfactory response in 2 of them, suggests that it may provide a slow but good therapeutic effect in some patients [15]. Another recently published case report provides support to the efficacy of ustekinumab in palmoplantar pustulosis [16].…”

Section: Discussionmentioning

confidence: 99%

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Puig¹,

Morales-Múnera²,

López‐Ferrer³

et al. 2012

Dermatology

View full text Add to dashboard Cite

Background: Therapy with tumour necrosis factor α (TNF) inhibitors can be associated with paradoxical reactions, namely the de novo development or flaring of conditions that usually respond to these therapeutic agents, such as arthritis, inflammatory bowel disease, sarcoidosis or psoriasis. They are considered a class effect of these drugs, and their incidence ranges from 1 to 5%, with paradoxical psoriasis (psoriasis vulgaris, palmoplantar pustulosis, scalp psoriasis and their combinations) being most frequently reported. Treatment of paradoxical psoriasis often requires withdrawal of the inducing drug and switching to another anti-TNF agent, but often this cannot avoid recurrence or persistence of the rash and/or loss of the therapeutic effect on the underlying condition. Case Report: We report on a 47-year-old woman who developed incapacitating palmoplantar pustulosis and psoriasis vulgaris flare with severe scalp and nail involvement after 5 months of treatment with adalimumab for psoriatic arthritis. Several treatments, including topical corticosteroids, photochemotherapy, ciclosporin, acitretin and etanercept 50 mg twice a day for 1 month, were ineffective or not tolerated. Treatment with ustekinumab 45 mg provided complete resolution of skin lesions with acceptable therapeutic control of the arthritis, with a follow-up duration of 16 months. Conclusion: A review of the reported cases suggests that this may be a therapeutic option in patients who develop paradoxical psoriasis while under treatment for arthritis or Crohn’s disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Puig¹,

Morales-Múnera²,

López‐Ferrer³

et al. 2012

Dermatology

View full text Add to dashboard Cite

show abstract

“…As with other biological agents, ustekinumab was only developed in adult plaque psoriasis, and there are limited data on its efficacy in other forms of psoriasis. Recently, Gerdes et al [5] reported 4 cases with palmoplantar pustulosis with improvement in 2 of the 4.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Ustekinumab in Palmoplantar Psoriasis

et al. 2010

View full text Add to dashboard Cite

“…At present, biotherapies including ustekinumab are regarded as a second-line treatment for patients with challenging regional psoriasis not responding to conventional management [17, 67, 68]. Anyway, the cost-effectiveness ratio is important to consider and any potential adverse event to ustekinumab should be considered with caution [69].…”

Section: Discussionmentioning

confidence: 99%

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease

Hermanns‐Lê

Berardesca

Pierard

et al. 2012

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

In some patients, psoriasis appears refractory to many treatments, particularly when the disease is confined to some specific body regions. In this respect, palmoplantar psoriasis and palmoplantar pustulosis are possibly related conditions in their immunopathomechanisms involving Il-12, IL-23, and Th17. Nail psoriasis and scalp psoriasis are two other particular psoriasis manifestations. Accordingly, ustekinumab was tested in a few of these patients. The present paper is limited to peer-reviewed case reports. Data were not supported by bioinstrumental assessments and controlled trials. Overall, they are indicative of potential efficacy. The cost-effectiveness and the risk-benefit assessments merit further investigations.

show abstract

Ustekinumab in the treatment of palmoplantar pustulosis

Cited by 73 publications

References 14 publications

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review

Efficacy of Ustekinumab in Palmoplantar Psoriasis

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease

Contact Info

Product

Resources

About